Related Experiment Videos
An open study of Timentin for the initial treatment of serious infections
Abstract:
Fifty patients were treated for suspected serious bacterial infection with Timentin 3.2 g 6-8-hourly. Three patients did not complete a minimum of 48 h treatment. Pathogens were isolated from 28 of the remaining 47 patients; 13 were resistant to ticarcillin but fully sensitive to Timentin; six of these isolates were Staphylococcus aureus. Five of the patients with Timentin-sensitive organisms or no significant growth failed to respond or relapsed after Timentin but also failed on subsequent therapy. An additional patient relapsed because of inadequate duration of treatment and one patient, with salmonella enteritis, became an asymptomatic carrier. The Timentin-resistant organisms were a Pseudomonas aeruginosa which responded to ceftazidime, a Klebsiella pneumoniae which was of doubtful clinical significance and an Escherichia coli which caused a relapse of pyelonephritis 16 days after apparently successful treatment with Timentin. No serious adverse reactions were seen. Timentin was effective against ticarcillin-resistant organisms but its final role will depend on the prevalence and significance of in-vitro resistance to the combination amongst Enterobacteriaceae and pseudomonads.
Insights
Timentin effectively treated serious bacterial infections, including those resistant to ticarcillin. However, some patients relapsed, highlighting the need to monitor for Timentin resistance in specific bacteria.
Area of Science:
- Infectious Diseases
- Pharmacology
- Bacteriology
Background:
- Serious bacterial infections require effective antibiotic treatment.
- Ticarcillin resistance can complicate treatment regimens.
- Timentin, a combination antibiotic, was investigated for its efficacy.
Purpose of the Study:
- To evaluate the clinical effectiveness and safety of Timentin in treating serious bacterial infections.
- To assess Timentin's activity against ticarcillin-resistant pathogens.
- To identify potential treatment failures and adverse reactions associated with Timentin therapy.
Main Methods:
- A prospective study involving 50 patients with suspected serious bacterial infections.
- Patients received Timentin 3.2 g every 6-8 hours.
- Pathogen isolation, antimicrobial susceptibility testing, and clinical response assessment were performed.
Main Results:
- Timentin demonstrated efficacy against 13 ticarcillin-resistant isolates, including Staphylococcus aureus.
- Five patients with Timentin-sensitive organisms failed to respond or relapsed.
- Timentin-resistant organisms included Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli, with one case of relapsed pyelonephritis.
Conclusions:
- Timentin is effective against ticarcillin-resistant bacteria.
- Treatment failures and relapses occurred in a subset of patients.
- The clinical utility of Timentin depends on the prevalence and significance of in vitro resistance in Enterobacteriaceae and pseudomonads.